# Advanced CRISPR Applications: A Review

Ce fichier demontre les differentes syntaxes de citations supportees, incluant le groupement automatique des citations adjacentes.

## Introduction

Gene editing technologies have transformed modern medicine. Several recent studies have explored various aspects of CRISPR-Cas9 therapy (1–3).

> **Resultat attendu avec style numerique:** Les citations adjacentes sont automatiquement groupees en `(1-3)` au lieu de `(1) (2) (3)`.

## Off-Target Effects

One of the main concerns with CRISPR is off-target editing. Basit et al. (1) extensively reviewed the challenges and strategies for precision DNA editing. Their work highlights the importance of careful guide RNA design.

## Delivery Methods

Efficient delivery remains a challenge. Kim et al. (2) developed lipid-silica hybrid nanoparticles for CRISPR delivery. This approach complements the high-fidelity Cas9 variants described by Qi et al. (3).

## Therapeutic Potential

The therapeutic applications of CRISPR are vast (4,5). As noted earlier by Basit et al. (1), minimizing off-target effects is crucial for clinical translation.

## Discussion

Multiple groups have contributed to advancing CRISPR technology (1,3,4). The work by Basit et al. (1) on off-target effects, combined with the delivery innovations from Kim et al. (2), suggests that clinical applications are within reach.

---

## Exemples de syntaxes de groupement

Les exemples de syntaxe sont documentes dans `overview.md`. Voici une demonstration avec de vraies citations:

### Citations adjacentes groupees

Ces trois citations adjacentes: (1–3)
sont rendues comme un groupe `(1-3)` au lieu de `(1) (2) (3)`.

### Citations non-groupees (separees par texte)

Voir (1), puis voir aussi (2).

Ces deux citations sont separees par du texte/ponctuation, donc elles ne sont PAS groupees.

---

## Conclusion

CRISPR-Cas9 continues to evolve rapidly. From the foundational work on precision (1) to novel delivery systems (2) and therapeutic applications (4,5), the field shows tremendous promise.

## References

<div class="csl-bib-body">
  <div class="csl-entry">
    <div class="csl-left-margin">1. </div><div class="csl-right-inline">Basit A, Zhu J, Zheng W. Assessing off-target effects in CRISPR/Cas9: challenges and strategies for precision DNA editing. Arch Microbiol. Germany;. 2026;208(2):114. doi: 10.1007/s00203-025-04687-4.</div>
  </div>
  <div class="csl-entry">
    <div class="csl-left-margin">2. </div><div class="csl-right-inline">Kim M, Kim K, Lee J, et al. FAST-CRISPR: Fusogenic Association and Secured Transfection of CRISPR/Cas9 Ribonucleoproteins Using Lipid-Silica Hybrid Nanoparticles for Therapeutic Genome Editing. Small. Germany;. 2026;e11362. doi: 10.1002/smll.202511362.</div>
  </div>
  <div class="csl-entry">
    <div class="csl-left-margin">3. </div><div class="csl-right-inline">Qi S, Wei L, Ding Z, et al. Targeting transthyretin by one Cas9 variant with superfidelity and broad compatibility. Sci Adv. United States;. 2026;12(1):eadu6505. doi: 10.1126/sciadv.adu6505.</div>
  </div>
  <div class="csl-entry">
    <div class="csl-left-margin">4. </div><div class="csl-right-inline">Bharti A, Mudge J. Therapeutic applications of CRISPR-Cas9 gene editing. Front Genome Ed. Switzerland;. 2025;7:1724291. doi: 10.3389/fgeed.2025.1724291.</div>
  </div>
  <div class="csl-entry">
    <div class="csl-left-margin">5. </div><div class="csl-right-inline">Sattarov R, Kuznetsov A, Klimko V, et al. The Template-Jumping Editing Approach in <i>F9</i>-Associated Hemophilia B Gene Therapy. Int J Mol Sci. Switzerland;. 2025;26(24):11916. doi: 10.3390/ijms262411916.</div>
  </div>
</div>